Literature DB >> 30859278

[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges].

Wolf-Dieter Ludwig1.   

Abstract

Mesh：

Year:  2019        PMID： 30859278     DOI： 10.1007/s00108-019-0578-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  19 in total

1.  Rare diseases and orphan drugs.

Authors:  Irena Melnikova
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

2.  Does orphan drug legislation really answer the needs of patients?

Authors:  Marlene E Haffner; Josep Torrent-Farnell; Paul D Maher
Journal:  Lancet       Date:  2008-06-14       Impact factor: 79.321

3.  Access to orphan drugs despite poor quality of clinical evidence.

Authors:  Alain G Dupont; Philippe B Van Wilder
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

4.  Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.

Authors:  Roberta Joppi; Vittorio Bertele'; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

5.  Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.

Authors:  Aaron S Kesselheim; Jessica A Myers; Jerry Avorn
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

6.  Pivotal studies of orphan drugs approved for neurological diseases.

Authors:  Jun Mitsumoto; E Ray Dorsey; Christopher A Beck; Karl Kieburtz; Robert C Griggs
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

7.  The European challenges of funding orphan medicinal products.

Authors:  Márta Szegedi; Tamás Zelei; Francis Arickx; Anna Bucsics; Emanuelle Cohn-Zanchetta; Jurij Fürst; Maria Kamusheva; Pawel Kawalec; Guenka Petrova; Juraj Slaby; Ewa Stawowczyk; Milan Vocelka; Ingrid Zechmeister-Koss; Zoltán Kaló; Mária Judit Molnár
Journal:  Orphanet J Rare Dis       Date:  2018-11-06       Impact factor: 4.123

Review 8.  Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.

Authors:  Todd Gammie; Christine Y Lu; Zaheer Ud-Din Babar
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

9.  Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.

Authors:  Viviana Giannuzzi; Annalisa Landi; Enrico Bosone; Floriana Giannuzzi; Stefano Nicotri; Josep Torrent-Farnell; Fedele Bonifazi; Mariagrazia Felisi; Donato Bonifazi; Adriana Ceci
Journal:  BMJ Open       Date:  2017-09-11       Impact factor: 2.692

10.  Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.

Authors:  Kiu Tay-Teo; André Ilbawi; Suzanne R Hill
Journal:  JAMA Netw Open       Date:  2019-01-04
View more
  1 in total

1.  [Orphan drugs].

Authors:  Jürgen R Schäfer; Claus F Vogelmeier
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.